Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized,…
By G. Batist, G. Ramakrishnan, C. Rao, A. Chandrasekharan, J. Gutheil, T. Guthrie, Pankaj Shah, A. Khojasteh, M. Nair, K. Hoelzer and 3 more. Journal of Clinical Oncology, 2001
664 citations recorded by the source corpus.
Subfields: Biomaterials, Cardiology and Cardiovascular Medicine, Oncology
View Paper: https://www.semanticscholar.org/paper/cf9dbd9591a243b486d2dde83ec7e9f9cd5d0a42
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomaterials
In Oncology
Citations in the corpus
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity (2004, background): “…formulation was clearly associated with a lower incidence of cardiotoxicity (median cumulative anthracycline dose at onset was more than 2220 mg/m2 in the liposomal DOX/cyclophosphamide arm versus 480 mg/m2 in the free DOX/cyclophosphamide arm) (Batist et al., 2001). c. Liposomal Daunorubicin.”
- Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic (2009, neutral): “Chem Commun (Camb) 2001 Dec 7;(23):2442–3.”
- Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. (2004, background): “Another option to conventional anthracyclines is TLC-D99, a nonpegylated liposomally encapsulated formulation of doxorubicin [24, 25].”
- Liposomal Formulations in Clinical Use: An Updated Review (2017, neutral): “Batist and co-workers [33] conducted another multicentric designed clinical trial in patients with metastatic breast cancer, in which a Myocet® (60 mg/m2) and cyclophosphamide (600 mg/m2) combination was compared with a free DOX and cyclophosphamide combination at the same dose.”
- Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “None of the patients treated with Myocet suffered congestive heart failure, although five cases were found in the conventional DOX-treated patients (Batist et al., 2001).”
- Organ-on-a-Chip Platforms for Studying Drug Delivery Systems (2014, neutral): “Multicellular tumor cylindroids have been used to study the effect of charge on the uptake of fluorescein isothiocyanate (FITC) or doxorubicin (DOX)-conjugated AuNPs loaded with drugs, where diffusion is permitted only from the periphery to the center [38].”